Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Government Resource

FDA cautions about dose confusion and medication errors for antibacterial drug Zerbaxa (ceftolozane and tazobactam).

Food and Drug Administration; FDA.

Save
Print
June 3, 2015
Food and Drug Administration; FDA.

Dosing information on drug labels should be clearly articulated to prevent confusion. This announcement raises awareness of a drug strength labeling change regarding active ingredients in the antibacterial drug Zerbaxa to improve dosing accuracy.

Save
Print
Cite
Citation

Food and Drug Administration; FDA.

Related Resources From the Same Author(s)
Related Resources